RVMD · NASDAQ · STOCK
Revolution Medicines (RVMD) Stock Analysis
$189.68
52W $47.45 – $224.31
54/100
$40.34B
-21.4
1.40
Is RVMD Bullish or Bearish?
Mixed.
Innellis AI committee rates Revolution Medicines, Inc. (RVMD) Watch with a composite score of 54/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +6.00 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.00 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock. Growth Analyst remains cautious — 4 consecutive earnings misses -- execution concerns. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 9.4x prices in significant intangible value — Value
- ROE of only -54.1% -- cheap may mean cheap for a reason — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
54/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 72%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 9.4x prices in significant intangible value
Growth Analyst
bearish
28
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.16) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 52.3 to 54.0.
- Committee agreement increased notably from 33% to 50%.
- Bearish pressure eased: 1 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Technical Analyst: stance bearish->neutral; score 38->48 (+10).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
31.0
Neutral
MACD Histogram
-1.207
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Lh Ll
Support
$91.59
Resistance
$224.18
Bollinger %B
0.13
Inside Bands
Price vs Moving Averages
EMA 9
$197.80
Below
EMA 21
$200.17
Below
EMA 50
$198.03
Below
EMA 200
$154.95
Above
Fundamental Analysis
Valuation
67
Growth
11
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-21.4×
P/B Ratio
15.36×
PEG Ratio
0.38
Dividend Yield
0.00%
52W High
$224.31
52W Low
$47.45
Quality & Growth
ROE
-6935.0%
ROA
-4804.8%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.25
AI Fundamental Assessment
P/E ratio of -21.4 (inexpensive relative to a 15-40x range); Price-to-book of 15.4x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -69.3%; Return on assets of -48.0%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 11.38 (healthy short-term liquidity); Debt-to-equity of 0.25; Free cash flow per share is negative (-5.84); Most recent quarter missed estimates by 51.7%; 4 consecutive earnings misses; EPS growth decelerating (-23.1% -> -33.6% QoQ); Analyst estimates falling over recent quarters
Get the Full RVMD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →